

Special Issue

Pandemics-Born Revolution in the Preclinical and Clinical Trials of Microbial Vaccines

Message from the Guest Editors

This issue is welcoming submissions of experimental papers, short communications, reviews and activity reports focusing on the above problems. We specifically welcome submissions which consider the impact of SARS-CoV-2 pandemics on:

- Development of plug and play platforms approach
- Future vaccine discovery/development; harnessing the current momentum for vaccine development to create new vaccine platforms
- Novel vaccines/technologies for accommodating emerging SARS-CoV-2 variants
- Novel vaccines/technologies against other common and emerging (re-emerging) pathogens
- Development of animal models to test vaccine efficacy
- Vaccine manufacture and upscale in the future
- Formulations that aid the stability of vaccines facilitating distribution to less accessible and low resource countries

Guest Editors

Dr. Maria G. Isaguliants
Prof. Dr. Felicity Jane Burt
Dr. Ilya Gordeychuk

Deadline for manuscript submissions

closed (31 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/129976

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).